NorthCrest Asset Manangement LLC Buys 1,354 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

NorthCrest Asset Manangement LLC increased its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 2.6% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 53,885 shares of the medical research company's stock after acquiring an additional 1,354 shares during the quarter. NorthCrest Asset Manangement LLC's holdings in Thermo Fisher Scientific were worth $26,813,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also added to or reduced their stakes in the company. Semus Wealth Partners LLC increased its position in shares of Thermo Fisher Scientific by 4.0% during the fourth quarter. Semus Wealth Partners LLC now owns 471 shares of the medical research company's stock valued at $245,000 after buying an additional 18 shares during the period. Proactive Wealth Strategies LLC grew its holdings in shares of Thermo Fisher Scientific by 2.7% during the 4th quarter. Proactive Wealth Strategies LLC now owns 753 shares of the medical research company's stock worth $392,000 after acquiring an additional 20 shares during the period. Cassaday & Co Wealth Management LLC raised its position in shares of Thermo Fisher Scientific by 0.9% in the 4th quarter. Cassaday & Co Wealth Management LLC now owns 2,286 shares of the medical research company's stock worth $1,189,000 after acquiring an additional 20 shares in the last quarter. Callan Capital LLC boosted its position in shares of Thermo Fisher Scientific by 2.7% during the fourth quarter. Callan Capital LLC now owns 773 shares of the medical research company's stock valued at $402,000 after purchasing an additional 20 shares in the last quarter. Finally, One Charles Private Wealth Services LLC grew its stake in Thermo Fisher Scientific by 4.2% in the fourth quarter. One Charles Private Wealth Services LLC now owns 499 shares of the medical research company's stock worth $260,000 after purchasing an additional 20 shares during the period. Institutional investors own 89.23% of the company's stock.

Thermo Fisher Scientific Stock Performance

Shares of Thermo Fisher Scientific stock traded up $2.39 during trading on Monday, hitting $405.15. 1,972,887 shares of the company's stock traded hands, compared to its average volume of 1,931,953. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.66 and a quick ratio of 1.29. Thermo Fisher Scientific Inc. has a 1 year low of $390.50 and a 1 year high of $627.88. The stock has a market capitalization of $152.94 billion, a P/E ratio of 24.51, a PEG ratio of 2.99 and a beta of 0.78. The business has a 50-day simple moving average of $416.55 and a 200-day simple moving average of $491.11.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its earnings results on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.10 by $0.05. The business had revenue of $10.36 billion for the quarter, compared to analysts' expectations of $10.23 billion. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. The business's revenue for the quarter was up .2% on a year-over-year basis. During the same period last year, the firm posted $5.11 earnings per share. As a group, analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, July 15th. Shareholders of record on Friday, June 13th will be given a $0.43 dividend. The ex-dividend date of this dividend is Friday, June 13th. This represents a $1.72 annualized dividend and a yield of 0.42%. Thermo Fisher Scientific's payout ratio is 10.09%.

Insiders Place Their Bets

In other news, EVP Gianluca Pettiti sold 300 shares of the firm's stock in a transaction dated Monday, April 28th. The stock was sold at an average price of $429.93, for a total value of $128,979.00. Following the transaction, the executive vice president now owns 23,167 shares of the company's stock, valued at $9,960,188.31. This trade represents a 1.28% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 0.33% of the company's stock.

Analysts Set New Price Targets

A number of equities analysts have issued reports on the company. The Goldman Sachs Group set a $610.00 price objective on Thermo Fisher Scientific and gave the stock a "buy" rating in a report on Wednesday, April 23rd. Stifel Nicolaus decreased their price objective on Thermo Fisher Scientific from $665.00 to $620.00 and set a "buy" rating for the company in a report on Thursday, April 24th. Barclays decreased their price objective on Thermo Fisher Scientific from $620.00 to $475.00 and set an "equal weight" rating for the company in a report on Thursday, April 10th. Wells Fargo & Company decreased their price objective on Thermo Fisher Scientific from $580.00 to $570.00 and set an "overweight" rating for the company in a report on Thursday, April 24th. Finally, Royal Bank of Canada decreased their price objective on Thermo Fisher Scientific from $651.00 to $637.00 and set an "outperform" rating for the company in a report on Thursday, April 24th. Four equities research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $605.30.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.